Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the…
Significant advances have elevated breast cancer care to new levels of success and complexity. One such advance has been the…
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial…
Irene Ghobrial, MD of the Dana-Farber Cancer Institute (DFCI), discusses progression of multiple myeloma (MM), which comes from conditions such…
Howard Burris, MD from Sarah Cannon, Nashville, TN discusses the use and benefits of liquid biopsies, which include being less…
Howard Burris, MD from Sarah Cannon, Nashville, TN discusses TGR-1202 for chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL). TGR-1202…
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the results of a Phase III trial…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how the definition of elderly is less…
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses current research in acute lymphoblastic leukemia (ALL).…
Jacqueline Barrientos, MD from Northwell Health, New York, NY discusses drug treatment options for chronic lymphocytic leukemia (CLL), specifically ibrutinib,…
Jacqueline Barrientos, MD from Northwell Health, New York, NY discuss a placebo-controlled study of idelalisib in combination with bendamustine plus…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses the unmet medical need of patients with polycythemia vera…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses Momelotinib at the European Hematology Association (EHA) 2016 Annual…
Bruno Paiva, PhD from the University of Navarra, Pamplona, Spain outlines his presentation on the role of minimal residual disease…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines tumor lysis syndrome as a side-effect of venetoclax in treatment…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany outlines current clinical research in chronic lymphocytic leukemia (CLL). Dr Eichhorst…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses the economic burden of treating chronic lymphocytic leukemia (CLL). A…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses using venetoclax in the treatment of patients with chronic lymphocytic…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses updates in current clinical trials being undertaken in the field…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses the treatment of elderly CLL patients. In the beginning of…
Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discussing treatment options for co-morbid chronic lymphocytic leukemia (CLL) patients. These…
Are any immunotherapy approaches currently available to treat advanced prostate cancer patients? Andrew Schorr, Patient Power Founder and Host, leads…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses momelotinib at the European Hematology Association (EHA) 2016 Annual…
Robin Foà , MD from the Sapienza University, Rome, Italy gives an overview of the session on ‘Biosimilars: shaping the future…
Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses alternative options for the treatment for chronic lymphocytic leukemia (CLL). Similar…
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discusses the current progress being made in multiple myeloma (MM) research.…
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses the efficacy and safety of the CD19…
Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD discusses treatment of acute myeloid leukemia (AML) patients. Although…
Stephan Grupp, MD, PhD from Children’s Hospital of Philadelphia, Philadelphia, PA outlines his work at the University of Pennsylvania. Currently…
Stephan Grupp, MD, PhD from Children’s Hospital of Philadelphia, Philadelphia, PA discusses his research into pediatric acute lymphoid leukemia (ALL).…
Robin Foà , MD from the Sapienza University, Rome, Italy discusses the advances in the diagnostics and treatment of acute lymphocblastic…
Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD discusses a common question that acute myeloid leukemia (AML)…
Robin Foà , MD from the Sapienza University, Rome, Italy discusses the question of how the trials on biosimilars should be…
Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses the importance of PI3 kinase, specifically the delta isoform in chronic…
Robin Foà , MD from the Sapienza University, Rome, Italy discusses whether biosimilars may help increase the access to novel drugs.…
Mark Levis, MD, PhD from The Johns Hopkins University, Baltimore, MD spoke on the lack of evolution in acute myeloid…
Peter Hillmen, MD, PhD from St. James’ University Hospital, Leeds, UK discusses the debate ‘Can we cure CLL today?’ held…
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK describes the role and actions of the precision medicine for…
Michael Hallek, MD from the University of Cologne, Cologne, Germany gives an overview of the International Workshop on Chronic Lymphocytic…
Press brief by Christine Chomienne, MD, PhD of the Paris Diderot University, Paris, France, at the 2016 Annual Meeting of…
Press brief by Ernest Turro, PhD of the NHS Blood and Transplant, Cambridge, UK, at the 2016 Annual Meeting of…
Press brief by Nina Toft, MD, PhD of the Rigshospitalet and Herlev Hospital, Copenhagen, Denmark, at the 2016 Annual Meeting…
Press brief by Mette Hazenberg, MD, PhD of the Academic Medical Center, Amsterdam, Netherlands, at the 2016 Annual Meeting of…
Press brief by Amir Fathi, MD of the Massachusetts General Hospital, Boston, MA, on SGN-CD33A combined with hypomethylating therapy, which…
Press brief by Federica Melazzini, MD of the University of Pavia, Pavia, Italy, at the 2016 Annual Meeting of the…
Press brief by Jeffrey Jones, MD, MPH of the The Ohio State University, Columbus, OH, on a cross-study analysis of…
EHA 2016: Press brief by Anas Younes, MD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the…
Press brief by Daniel Goldstein, MD of the Rabin Medical Center, Petah Tikva, Israel, at the 2016 Annual Meeting of…
Press brief by Tuya Pal, MD of the Moffitt Cancer Center, Tampa, FL, at the 2016 Annual Meeting of the…
Press brief by Ronald Chen, MD, MPH of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, at the 2016…
Press brief by Fabrice Denis, MD, PhD of the Jean Bernard Center, Le Mans, France, at the 2016 Annual Meeting…
Press brief by Charles Rudin, MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY, at the 2016…
Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of…
Press brief by Arjun Vasant Balar, MD of the NYU Langone Medical Center, New York, NY, at the 2016 Annual…
Press brief by Nikhil Wagle, MD of the Dana-Farber Cancer Institute, Boston, MA, at the 2016 Annual Meeting of the…
Press brief by John Hainsworth, MD of the Sarah Cannon Research Institute, Nashville, TN, at the 2016 Annual Meeting of…
Ramaswamy Govindan, MD of Washington University Medical School describes the importance to biopsy a growing lesion in lung cancer
Evan Yu, MD of Seattle Cancer Care Alliance notes that some patients saw dramatic improvement in IMvigor210 trial
Petros Grivas, MD of Cleveland Clinic asked the question Are safety and adverse event profile appears similar between early trials…
Ramaswamy Govindan, MD of Washington University Medical School updates research on Small Cell Lung Cancer agents at ASCO 2016
Fadi Braiteh, MD Comprehensive Cancer Centers of Nevada discusses Previous cytotoxin patients thought they were on placebo during atezolizumab trial…
Evan Yu, MD of Seattle Cancer Care Alliance discusses IMvigor210 response rate durability of response and stable disease
Alexander Spira, MD of Virginia Cancer Specialists gives an overview of the POPLAR trial endpoints median duration of response overall…
Nathan Pennell, MD of Cleveland Clinic discusses Second line treatment of NSCLC patients before immuno-oncology
Dr. Petros Grivas, MD of Cleveland Clinic mentions that all comers are eligible in second line Atezolizumab
Dr. Ramaswamy Govindan, MD from Washington University Medical School gives an update at ASCO 2016 on MET in NSCLC
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses diffuse large B-Cell lymphoma (DLBCL). A study conducted in…
Press brief by Laura Franco, MD of the University of Perugia, Perugia, Italy, at the 2016 Annual Meeting of the…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ talks about why doctors should use social media channels such as…
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses the pooled analysis of NCT01236391, NCT01599949 and NCT01646021 trials…
Press brief by Klaus Metzeler, MD of the Ludwig-Maximilians University, Munich, Germany, at the 2016 Annual Meeting of the European…
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK gives an overview of the subjects discussed during the European…
Press brief by Max Topp, MD of the University of Würzburg, Würzburg, Germany, at the 2016 Annual Meeting of the…
Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK stresses the importance of educating patients about adverse effects of…
Press brief by Meletios Dimopoulos, MD of the University of Athens, Athens, Greece, at the 2016 Annual Meeting of the…
” Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses his participation in the joint symposia regarding high…
Press brief by Andreas Engert, MD of the University Hospital of Cologne, Cologne, Germany, at the 2016 Annual Meeting of…
Press brief by Tony Green, MD, PhD of the Cambridge Institute for Medical Research, Cambridge, UK, at the 2016 Annual…
Giuseppe Saglio, MD of the University of Turin, Turin, Italy provides an overview of the results of the Phase III…
In this Ask the Expert segment, Terry is concerned about his mothers treatment and side effects. He wants to know…
Evan Yu, MD of Seattle Cancer Care notes that some patients saw dramatic improvement in IMvigor210 trial
From our MPN Ask the Expert series, Patient Power viewer, Jane, asks a question about using iron supplements for MPN…
In this Ask the Expert segment, Terry is concerned about his mothers treatment and side effects. He wants to know…
POPLAR trial success leads to larger OAK study
Autoimmune can be delayed in immunotherapy
Alexander Spira, MD of the Cleveland Clinic discusses the results of Phase II POPLAR trial evaluating Atezolizumab in advanced NSCLC
Nathan Pennell, MD of Cleveland Clinic discusses his experience with Nivolumab and Pembrolizumab in the second line therapy of your…
Omid Hamid, MD of the Angeles Clinic discusses the phase III NEMO trial and the novel MEK inhibitor Binimetinib
Petros Grivas, MD of Cleveland Clinic discusses the efficacy of Atezolizumab within cohort 2 of IMvigor210
Arjun V. Balar, MD of NYU Langone Medical Center discusses the percentage of patient with urothelial cancer that are cisplatin…
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers of Nevada describers the differences in Squamous Cell Carcinomas versus the Non-Squamous…
Dr. Ramaswamy Govindan, MD of the Washington University Medical School gives an update on BRAF in NSCLC from ASCO 2016
Dr. Heather Wakelee, MD of the Stanford School of Medicine outlines the best way to test newly diagnosed NSCLC in…
Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discussing the characteristics and mode of action of Ibrutinib.…
Jeffrey Jones, MD, MPH from the Ohio State University, Columbus, OH discusses the current thought on treating relapsed and refractory…
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discussing treatment options for relapsed and refractory myeloma at the European…
Giuseppe Saglio, MD from University of Turin, Turin, Italy discusses the influence of TKI therapy on the treatment of chronic…
Antonio Palumbo, MD from the University of Turin, Turin, Italy talks about when daratumumab will be available in combination with…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses research into JAK inhibitors specifically Ruxolitinib, Pacritinib, and Momelotinib.…
Antonio Palumbo, MD from the University of Turin, Turin, Italy discusses the place of daratumumab in the current treatment landscape…
Niels van de Donk, MD, PhD from the University Medical Center, Amsterdam, Netherlands discusses three trials of daratumumab in multiple…
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses janus kinase (JAK) inhibitors at the European Hematology Association…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines the importance of blinatumomab and inotuzumab…
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses the current research on immunotherapy in multiple myeloma (MM). The…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines his talk on minimal residual disease…
Antonio Palumbo, MD from the University of Turin, Turin, Italy gives an overview of the results of the Phase III…
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines the clinical practice of acute lymphoblastic…
Shaji Kumar, MD from the Mayo Clinic, Rochester, MN discusses venetoclax and the future of treatment of multiple myeloma (MM).…
Simon Rule, MD from Derriford Hospital, Plymouth, UK discusses current mantle cell lymphoma (MCL) news, including the novel results from…
Valeria Santini, MD from University of Florence, Florence, Italy outlines the mode of action of hypomethylating agents – azacitidine and…
Michael Hallek, MD from the University of Cologne, Cologne, Germany discusses the debate around whether chronic lymphocytic leukemia (CLL) is…
Marek Trneny, MD, PhD from Charles University General Hospital, Prague, Czech Republic gives an overview of his talk on the…
Katja Weisel, MD from University Hospital Tuebingen, Tuebingen, Germany discusses the slowly progressing myeloma and outlines how there are clear…
Valeria Santini, MD from University of Florence, Florence, Italy discusses the treatment of myelodysplastic syndromes (MDS). In Europe azacitidine is…
Simon Rule, MD from Derriford Hospital, Plymouth, UK outlines his presentation on his work with ibrutinib. Prof Rule discusses the…
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL)…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK provides an overview of his talk on allogeneic…
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY outlines the limited progress in acute myeloid…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK discusses when a transplant is the most suitable…
Charles Craddock, CBE, FRCP, FRCPath, DPhil, from Queen Elizabeth Hospital, Birmingham, UK explains how epigenetic drugs may have a capacity…
Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, gives an overview of the CLL pilot run by…
Dr. Alexander Spira, MD of Virginia Cancer Specialists goes over the risk and benefit to blocking PD-L2
Dr. Robert Dreicer, MD of the University of Virginia highlights small molecule inhibitor trials within urothelial cancer
Dr. Arjun V. Balar, MD of NYU Langone Medical Center discusses using deficient mismatch repair in PD-L1 therapy for urothelial…
Dr. Evan Yu, MD of Seattle Cancer Care Alliance notes that some patient populations may respond better to atezolizumab and…
Dr. Omid Hamid, MD of The Angeles Clinic discusses new predictive markers in immunotherapy for melanoma
Dr. Petros Grivas, MD of Cleveland Clinic outlines how the higher levels of PD-L1 expression correlates with higher response rates
Dr. Ramaswamy Govindan, MD of Washington University Medical School gives an update on ALK+ lung cancer agents at ASCO 2016
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers of Nevada notes that autoimmune can be delayed in immunotherapy
Dr. Nathan Pennell, MD of Cleveland Clinic describes the safety and efficacy differences between PD-1 and PD-L1 inhibitors
Dr. Alexander Spira, MD of Virginia Cancer Specialists discusses the durable response of atezolizumab
Anna Schuh, MD, PhD, from the University of Oxford, discusses the importance of genomic analysis in chronic lymphocytic leukemia (CLL)…
Gail Roboz, MD from Weill Medical College of Cornell University, New York, NY discusses the availability of commercially available genetic…
George Follows, MA, BM, BCh, PhD, FRCP, FRCPath from Cambridge University Hospitals, Cambridge, UK gives an overview of the session…
Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the cost of new drugs in…
Dr. Heather Wakelee, MD of Stanford School of Medicine outlines the best way to test newly diagnosed NSCLC in the…
Petros Grivas, MD discusses anti PD-1 versus anti PD-L1 in urothelial carcinoma
Dr. Omid Hamid, MD of The Angeles Clinic presents updated results of KEYNOTE-001 006 and 029 for advanced melanoma
Robert Dreicer, MD of the University of Virginia answers the question why urothelial cancer for checkpoint inhibitor therapeutics
Dr. Fadi Braiteh, MD of Comprehensive Cancer Centers discusses the POPLAR results show statistic significant improvement in overall survival
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the research activities of the European Research…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses drug combinations for the treatment of chronic…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece gives an overview of the European Research Initiative…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about venetoclax for chronic lymphocytic leukemia (CLL).…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase III POLLUX trial on…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR discusses the use of FISH in…
Andrew Spencer, MD, PhD from the Monash University, Melbourne, Australia discusses the side effects of panobinostat in multiple myeloma (MM).…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy talks about the stratification of chronic lymphocytic leukemia…
Philippe Moreau, MD from the University Hospital of Nantes, Nantes, France gives an overview of his session on how monoclonal…
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses minimal residual disease (MRD) negativity in chronic…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA gives an overview of the Phase Ib/II study of ricolinostat…
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the progress of research in chronic lymphocytic…
Gareth Morgan, MD, FRCP, FRCPath, PhD from the UAMS Myeloma Institute, Little Rock, AR provides an overview of his talk…
Anna Schuh, MD, PhD, from the University of Oxford, UK, gives an overview of her talk on the advances in…
Francesco Forconi, MD, PhD from the University of Southampton, Southampton, UK gives an overview of his talk on the structure…
Andrew Spencer, MD, PhD from the Monash University, Melbourne, Australia provides an overview of his talk on epigenetics and HDAC…
As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek,…
As part of our coverage from the 2016 American Society of Clinical Oncology annual meeting, MPN experts Dr. Srdan Verstovsek,…
Expert Dr. Russell Szmulewitz of the University of Chicago Medical Center describes the endocrinology of prostate cancer and provides an…
Evan Yu, MD of Seattle Cancer Care Alliance goes over next steps after FDA approval for Atezelozimab
Even though there is a tremendous access to new drug therapies, doctors have yet to determine the best way to…
Discussed are the new IMWG Criteria in MRD testing in multiple myeloma, which is to be published in Lancet Oncology.…
Heather Wakelee, MD of Stanford Medicine discusses genetic heterogeneity and genomic alterations in KRAS mutated NSCLC
The doctors consider mSMART classification to look at high-, intermediate-, and standard-risk myeloma. They discuss, with the increasing depth of…
The third question of the series is Are you proactive regarding your patients possible comorbidities? In particular, the doctors consider…
The first question of the series is What is the impact of the new diagnostic criteria? The criteria to which…
Alexander Spira, MD of Virginia Cancer Specialists discusses PD-L1 expression in tumor and immune cells in the microenvironment from the…
Nathan Pennell, MD of Cleveland Clinic talks about the future of genotypical NSCLC immunotherapy
Dr. Omid Hamid, MD of The Angeles Clinic outlines the evidence that uveal melanoma is responsive to immunotherapy
Dr Arjun V. Balar, MD of NYU Langone Medical Center discusses how upper tract disease did better in IMVigor210 trial
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO)…
Is there hope for lung cancer patients with genetic alterations who have become resistant to therapies? On location at ASCO…
Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there…
Does knowing your molecular mutation in earlier stage lung cancer have any significance in selecting a treatment modality? Is there…
An expert panel, led by Dr. Tomasz Beer, explores research discussed at the 2016 American Society of Clinical Oncology (ASCO)…
What is the latest news on lung cancer immunotherapies? On location at ASCO 2016, lung cancer expert Dr. Charu Aggarwal…
Dr. Laura Chow discusses new combination therapies and molecularly targeted therapies, specifically in head and neck cancers.
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
Robert Dreicer, MD at University of Virginia Health System talks about how the Atezolizumab FDA approval will spur more studies…
Heather Wakelee, MD at The Stanford University Medical Center outlines the therapeutic options currently available for RET altered NSCLC from…
Alexander Spira, MD of Virginia Cancer Specialists goes over the future of Next-Gen sequencing and who will respond and who…
Nathan Pennell, MD at Cleveland Clinic discusses how to chose the most effective second line PD-1 or PD-L1 therapy in…
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg…
Omid Hamid, MD at The Angeles Clinic Combi-d and BRIM7 trials and the extended follow-up results
Arjun Balar, MD of NYU Langone gives an overview of IMvigor 210 cohort one data and results
Justin Stebbing, MD, MA, FRCP, FRCPath, PhD from Imperial College Healthcare NHS Trust, London, UK discusses developments in anti-PD-1 and…
Dr. Evan Yu, MD of University of Washington School of Medicine notes that smoking does not predispose higher response rate…
Dr. Heather Wakelee, MD of The Stanford University Medical Center Wakelee_MET in NSCLC including its over expression increased copy number…
Bruce Johnson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the challenges associated with developing effective treatments for patients with…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses the cost of drugs in multiple myeloma (MM) and the…
Rafael Fonseca, MD from the Mayo Clinic, Scottsdale, AZ discusses highlights in multiple myeloma (MM) at the American Society of…
Anas Younes, MD from the Memorial Sloan Kettering Cancer Center, New York, NY discusses the place of nivolumab and pembrolizumab…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
Constantine Tam, MBBS, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the preliminary results of…
Alexander Spira, MD of Virginia Cancer Specialists discusses mutation load and gene profiles appear to have a significant impact on…
Dr. Robert Dreicer, MD of the University of Virginia Health System gives an overview of PD-L1 expression on cancer cells…
Arjun Balar, MD of New York University Langone comments on deficient mismatch repair within urothelial cancer
Dr. Evan Yu, MD of the University of Washington School of Medicine outlines the IMvigor210 trial design and patient populaiton
Dr. Heather Wakelee, MD at The Stanford University Medical Center remarks on the E1505 trial results from ASCO 2016
Alexander Spira, MD of Virginia Cancer Specialist remarks on the many different combinations of immunotherapy drugs that are being being…
Omid Hamid, MD Director of the Melanoma Center at The Angeles Clinic goes over the advantages and disadvantages with Binimetinib…
Dr Robert Dreicer, MD of University of Virginia Health System highlights the importance of the FDA approval of Atezolizumab at…
Dr. Arjun Balar, MD of NYU Langone Medical Center discusses Bevacizumab in combination with chemotherapy in metastatic urothelial cancer at…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses his highlights for chronic…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses the safety of idelalisib…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA and recently elected president of the American Society of Clinical…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ discusses the issue of drug affordability and access in multiple…
William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of his…
Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ talks about his highlights from the American Society of Oncology (ASCO)…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ summarizes the results of two Phase III trials of daratumumab…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI shares some key Twitter tips for hematologists. Some of…
Sagar Lonial, MD from the Emory University Winship Cancer Institute, Atlanta, GA gives an overivew of the session ‘Are We…
Ruben Mesa, MD from the Mayo Clinic, Phoenix, AZ discusses updates to the Phase III PERSIST-1 trial of pacritinib for…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI discusses why hematologists should use social media. First Dr…
Michael Thompson, MD, PhD of the Aurora Health Care, Milwaukee, WI talks about the quality of the ASCO and ASH…
Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA outlines the side effects that may occur in chronic…
Keith Stewart, MB, ChB from the Mayo Clinic, Scottsdale, AZ gives an overview of his talk on the management and…
Jennifer Brown, MD, PhD from the Dana-Farber Cancer Institute, Boston, MA gives an overview of her talk on targeted therapy…
Elias Jabbour, MD from the The University of Texas MD Anderson Cancer Center, Houston, TX gives an overview of the…
Anas Younes, MD of Memorial Sloan Kettering Cancer Center, New York, NY talks about Checkmate 205, a registrational trial of…
Noopur Raje, MD from the Massachusetts General Hospital, Boston, MA discusses highlights on the in vivo drug screening session in…
Chng Wee Joo, MB, ChB, PhD, FRCP, FRCPath, FAMS from the National University Cancer Institute, Singapore discusses the current status…
Ray Comenzo, MD from the Tufts Medical Center, Boston, MA discusses the practical applications of genomics in multiple myeloma (MM)…
Nelson Leung, MD from the Mayo Clinic, Rochester, MN gives an overview of the common kidney problems in multiple myeloma…
Evangelos Terpos, MD, PhD, University of Athens, Athens, Greece gives an overview of the session on imaging and disease assessment…
In this Best of the Day interview from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Anne…
In this Best of the Day interview from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Anne…
In this Best of the Day interview from the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Anne…
This Best of the Day activity serves to provide a brief synopsis of the key points presented on thoracic oncology…
How do I participate in a clinical trial? Patient Power Founder and Host, Andrew Schorr, and head and neck cancer…
From our Ask the Expert series, MPN expert Dr. John Mascarenhas of Mount Sinai School of Medicine, answers Patient Power…
MPN specialist Dr. Mark Heaney discusses his role at Columbia University Medical Center and his approach to patient care. As…
The Oncotype DX® 21-gene Recurrence Score® result stratifies patients with breast cancer into low-, intermediate- and high-risk groups that correspond…
Bruce Johnson, MD, from Dana-Farber Cancer Institute, Boston, MA, explains the challenges associated with developing clinical trials for patients with…
At the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), Bruce Johnson, MD, from Dana-Farber Cancer Institute,…
Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA has recently been elected as President of the American Society…
The American Society of Clinical Oncology (ASCO) has recently elected Bruce Johnson, MD of the Dana-Farber Cancer Institute, Boston, MA…
Eric Low, Chief Executive at Myeloma UK, discusses how global collaboration is key in multiple myeloma research. According to Eric…
Eric Low, Chief Executive of Myeloma UK, explains the evolving strategies for improving the drug development process for therapies for…
Eric Low, Chief Executive of Myeloma UK, discusses recent advances in the development of new drugs for the treatment of…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Keith Kerr, BSc, MB…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Keith Kerr, BSc, MB…
At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 1316 April 2016, Suresh Ramalingam, MD, from…